Avenue Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Details) - shares	3 Months Ended
Significant Accounting Policies (Details) - shares	Mar. 31, 2019	Mar. 31, 2018
Total potential dilutive effect shares outstanding	1,315,317	984,999
Restricted stock units/awards
Total potential dilutive effect shares outstanding	1,065,317	714,999
Preferred shares
Total potential dilutive effect shares outstanding	250,000	250,000
Options
Total potential dilutive effect shares outstanding	0	20,000